Diligence memo · auto-generated · as of July 3, 2026
ImmVue Therapeutics Inc.
ImmVue Therapeutics Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
ImmVue Therapeutics Inc. operates in Biotechnology, based in TORONTO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ImmVue Therapeutics Inc. has raised $529K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $529K on 2024-01-31.
Most recent recorded round closed around 2024-01-31.
Valuation (modeled)modeled
Provath models ImmVue Therapeutics Inc. at approximately $3.2M (range $282K–$12M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.98× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (98% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.4 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.